Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation

Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation Oestrogen receptor (ER) is the driving transcription factor in 70% of breast cancer. Endocrine therapies targeting the ER represent one of the most successful anticancer strategies to date. In the clinic, novel targeted agents are now being exploited in combination with established endocrine therapies to maximise efficacy. However, clinicians must balance this gain against the risk to patients of increased side effects with combination therapies. This article provides a succinct outline of the principles of hormonal manipulation in breast cancer, alongside the key evidence that underpins current clinical practice. As the role of endocrine therapy in breast cancer continues to expand, the challenge is to interpret the data and select the optimal strategy for a given clinical scenario. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation

Johnston, Simon; Cheung, Kwok-Leung
Oncology and Therapy , Volume 6 (2) – Jul 10, 2018
Download PDF
16 pages

Loading next page...
 
/lp/springer-journals/endocrine-therapy-for-breast-cancer-a-model-of-hormonal-manipulation-v0Z4UJpER6
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0062-x
Publisher site
See Article on Publisher Site

Abstract

Oestrogen receptor (ER) is the driving transcription factor in 70% of breast cancer. Endocrine therapies targeting the ER represent one of the most successful anticancer strategies to date. In the clinic, novel targeted agents are now being exploited in combination with established endocrine therapies to maximise efficacy. However, clinicians must balance this gain against the risk to patients of increased side effects with combination therapies. This article provides a succinct outline of the principles of hormonal manipulation in breast cancer, alongside the key evidence that underpins current clinical practice. As the role of endocrine therapy in breast cancer continues to expand, the challenge is to interpret the data and select the optimal strategy for a given clinical scenario.

Journal

Oncology and Therapy – Springer Journals

Published: Jul 10, 2018

References

  • Tamoxifen for early breast cancer: an overview of the randomised trials
  • Estrogen receptor and breast cancer
    Sommer, S; Fuqua, SA
  • On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases
    Beatson, GT
  • On the mechanism of estrogen action
    Jensen, EV
  • Molecular mechanisms of antiestrogen action in breast cancer
    Jordan, VC
  • Tamoxifen (“Nolvadex”): a review
    Clemons, M; Danson, S; Howell, A
  • endometrial cancer in tamoxifen-treated breast-cancer patients—findings from the National Surgical Adjuvant Breast and Bowel Project (Nsabp) B-14
    Fisher, B
  • Landmark trials in endocrine adjuvant therapy for breast carcinoma
    Gradishar, W
  • Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer
    Miller, WR
  • Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial
    Lonning, PE
  • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
    Cuzick, J
  • Fulvestrant - a novel endocrine therapy for breast cancer
    Johnston, SJ; Cheung, KL
  • A good drug made better: the fulvestrant dose-response story
    Robertson, JF
  • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
    Robertson, JF
  • Bone turnover markers in postmenopausal breast cancer treated with fulvestrant—a pilot study
    Agrawal, A
  • Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    Baselga, J
  • Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
    Ciruelos Gil, EM
  • Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations
    Spring, LM
  • The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer
    Robertson, JF
  • Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
    Forward, DP
  • Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
    Bonneterre, J
  • Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
    Mouridsen, H
  • Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
    Paridaens, RJ
  • Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group
    Nabholtz, JM
  • Palbociclib and letrozole in advanced breast cancer
    Finn, RS
  • Optimising endocrine therapy in postmenopausal women with advanced breast cancer
    Yau, THL; Cheung, KL
  • Ribociclib as first-line therapy for HR-positive, advanced breast cancer
    Hortobagyi, GN
  • MONARCH 3: abemaciclib as initial therapy for advanced breast cancer
    Goetz, MP
  • Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
    Leo, A
  • Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study
    Robertson, JF
  • Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
    Robertson, JFR
  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
    Cristofanilli, M
  • Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
    Johnston, SR
  • FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer
    Bergh, J
  • Combination anastrozole and fulvestrant in metastatic breast cancer
    Mehta, RS
  • Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study
    Kaufman, B
  • Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer
    Ravdin, PM
  • PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer
    Wishart, GC
  • Prospective validation of a 21-gene expression assay in breast cancer
    Sparano, JA
  • Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study
    Jonat, W
  • Adjuvant ovarian suppression in premenopausal breast cancer
    Francis, PA; Regan, MM; Fleming, GF
  • Overview of adjuvant trials of aromatase inhibitors in early breast cancer
    Ingle, JN
  • Hormonal therapies for early breast cancer: systematic review and economic evaluation
    Hind, D
  • Extending aromatase-inhibitor adjuvant therapy to 10 years
    Goss, PE
  • Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: aTLAS, a randomised trial
    Davies, C
  • aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer
    Gray, RG
  • Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation
    Fisher, B
  • Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
    Fisher, B
  • Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study
    Eiermann, W
  • Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
    Smith, IE
  • Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer—the Pre-Operative “Arimidex” Compared to Tamoxilen (PROAC7) trial
    Cataliotti, L
  • Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized phase II study
    Kuter, I
  • Preoperative endocrine therapy for breast cancer
    Cheung, KL; Howell, A; Robertson, JFR
  • Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer
    Caudle, AS
  • Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial
    Bear, HD
  • Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
    Hind, D; Wyld, L; Reed, MW
  • Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines
    Wyld, L
  • The role of primary endocrine therapy in older women with operable breast cancer
    Johnston, SJ; Cheung, KL
  • Primary endocrine therapy as a treatment for older women with operable breast cancer—a comparison of randomised controlled trial and cohort study findings
    Morgan, JL; Reed, MW; Wyld, L
  • A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up
    Johnston, SJ
  • Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
    Hind, D
  • A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up
    Chakrabarti, J
  • Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre
    Syed, BM
  • Pathological features of primary breast cancer in the elderly based on needle core biopsies—a large series from a single centre
    Cheung, KL
  • Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts
    Syed, BM
  • Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ
    Clauser, P
  • Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
    Dowsett, M
  • Breast cancer chemoprevention: a network meta-analysis of randomized controlled trials
    Mocellin, S
  • Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
    Cuzick, J
  • Activating ESR1 mutations in hormone-resistant metastatic breast cancer
    Robinson, DR
  • Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERalpha metastatic breast cancer
    Magnani, L